The US Bankruptcy Court granted an order for the extension of the exclusivity periods for Sorrento Therapeutics, Inc. on October 18, 2023. As per the order, the debtor?s exclusivity period to file its plan and to solicit votes on its plan, have been extended by 42 days i.e. up to November 27, 2023 and January 26, 2024, respectively.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.009 USD | -18.18% | -25.00% | -92.71% |
04-10 | Sorrento Therapeutics, Inc. Emerged from Bankruptcy | CI |
03-15 | Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs | MT |
1st Jan change | Capi. | |
---|---|---|
-92.71% | 5.98M | |
+10.79% | 115B | |
+11.65% | 106B | |
-6.20% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.41% | 17.56B | |
-40.50% | 17.32B | |
+6.64% | 14.03B | |
+31.84% | 12.13B |
- Stock Market
- Equities
- SRNE Stock
- News Sorrento Therapeutics, Inc.
- Fourth Motion for Exclusivity Period Extension Approved For Sorrento Therapeutics, Inc.